Thursday, October 18, 2018
6:45am to 7:45am Registration and Breakfast
7:45am to 8:00am Seating
8:00am to 8:15am Welcome and Course Objectives

Samuel Z. Goldhaber, MD and Paul M Ridker, MD


8:15am to 8:35am Atherosclerosis: Biology and Pathophysiology

Peter Libby, MD

8:35am to 8:45am Discussion, Q&A
8:45am to 9:05am Aggressive Lipid Reduction to Minimize Cardiovascular Risk: Focus on PCSK9 Inhibitors

Marc Sabatine, MD, MPH

9:05am to 9:15am Discussion, Q&A
9:15am to 9:55am Anti-inflammatory Therapy to Reduce Risk of Cardiovascular Events and Lung Cancer: CANTOS and Canakinumab

Paul M Ridker, MD, MPH

9:55am to 10:05am Discussion, Q&A
10:05am to 10:25am Reduction of Cardiovascular Events by Decreasing Triglyceride Risk: The PROMINENT Trial

Aruna Pradhan, MD

10:25am to 10:35am Discussion, Q&A
10:35am to 11:05am Combined Antithrombotic and Antiplatelet Therapy to Reduce Cardiovascular Risk: COMPASS Trial Part I

John Eikelboom, MD

11:05am to 11:15am Discussion, Q&A
11:15am to 11:35am Coffee Break

Refreshments provided

11:35am to 12:05pm Combined Antithrombotic and Antiplatelet Therapy to Reduce Lower Extremity Arterial Disease: COMPASS Trial Part II

Sonia Anand, MD

12:05pm to 12:15pm Discussion, Q&A
12:15pm to 12:35pm Peripheral Arterial Disease and Thrombotic Risk: Ongoing and Future Trials

Umberto Campia, MD

12:35pm to 12:45pm Discussion, Q&A
12:45pm to 1:05pm Link Between Arterial and Venous Thrombosis

Samuel Z. Goldhaber, MD

1:05pm to 1:15pm Discussion, Q&A
1:15pm to 2:15pm Break for lunch*


2:15pm to 2:45pm Diagnosis of VTE: Clinical Assessment, D-Dimer Testing, and Optimal Strategy for Imaging

Henri Bounameaux, MD

2:45pm to 2:55pm Discussion, Q&A
2:55pm to 3:20pm Overview of PE: Epidemiology and Pathophysiology

Samuel Z. Goldhaber, MD

3:20pm to 3:30pm Discussion, Q&A
3:30pm to 3:55pm Anticoagulants for VTE: Focus on DOACs - Ongoing Challenges and Dilemmas

Samuel Z. Goldhaber, MD

3:55pm to 4:05pm Discussion, Q&A
4:05pm to 4:35pm Advanced Therapy: Beyond Anticoagulation

Gregory Piazza, MD, MS

4:35pm to 4:45pm Discussion, Q&A
4:45pm to 5:05pm Inferior Vena Cava Filters: The Good, The Bad, and The Ugly

Henri Bounameaux, MD

5:05pm to 5:15pm Discussion, Q&A
5:15pm to 6:15pm Break


6:15pm to 6:30pm Seating
6:30pm to 7:10pm One Brave Idea

Calum MacRae, MD, PhD

7:20pm to 8:30pm Dinner
Friday, October 19, 2018
7:00am to 7:45am Breakfast
7:45am to 8:00am Seating


8:00am to 8:20am DOAC Reversibility: Idaracizumab and Andexanet

Jean Connors, MD

8:20am to 8:30am Discussion, Q&A
8:30am to 8:50am Cancer and VTE: Beyond Low Molecular Weight Heparin Monotherapy

Jean Connors, MD

8:50am to 9:00am Discussion, Q&A
9:00am to 9:20am Heparin-Induced Thrombocytopenia

Jessica Rimsans, PharmD

9:20am to 9:30am Discussion, Q&A
9:30am to 9:50am Adherence to Thrombosis Medications: Problems with Polypharmacy and Promising Solutions

John Fanikos, RPh, MBA

9:50am to 10:00am Discussion, Q&A
10:00am to 10:20am Genetics 2018: What Every Clinician Should Know

Sekar Kathiresan, MD

10:20am to 10:30am Discussion, Q&A
10:30am to 10:50am Coffee break

Refreshments provided


10:50am to 11:30am Keynote: History of Anticoagulation

Eugene Braunwald, MD

11:30am to 11:40am Discussion, Q&A
11:40am to 12:10pm Mortality Reduction and Stroke Prevention in Atrial Fibrillation: Emergence of Biomarkers for Risk Stratification

Christian T. Ruff, MD, MPH

12:10pm to 12:20pm Discussion, Q&A
12:20pm to 12:40pm Single and Dual Antiplatelet Therapy

John Eikelboom, MD

12:40pm to 12:50pm Discussion, Q&A
12:50pm to 1:10pm Is Triple Therapy with Warfarin Dead?

Deepak L. Bhatt, MD, MPH

1:10pm to 1:20pm Discussion, Q&A
1:20pm to 2:30pm Break for lunch*


2:30pm to 3:00pm Reducing Cardiovascular Thrombotic Events with Contemporary Pharmacologic Therapy for Diabetes Mellitus

Deepak L. Bhatt, MD, MPH

3:00pm to 3:10pm Discussion, Q&A
3:10pm to 3:40pm Hypercoagulability Testing: When, Who, and Why

Jean Connors, MD

3:40pm to 3:50pm Discussion, Q&A
3:50pm to 4:20pm VTE: Fertility and Pregnancy

Gregory Piazza, MD, MS

4:20pm to 4:30pm Discussion, Q&A
4:30pm to 5:00pm VTE Prevention: Meeting the Critical Gap in Prophylaxis During the First Month after Hospitalization

Samuel Z. Goldhaber, MD

5:00pm to 5:10pm Discussion, Q&A
5:10pm Closing Remarks and Adjournment

*There are many convenient and varied lunch options within a short walking distance of the course.